Sarepta Reports Strong Q1 2026 Net Income Turnaround, Advances Pipeline & Reaffirms FY Guidance
SRPT has more than doubled off its 52-week low of $10.415.
Summary
Sarepta Therapeutics reported a strong Q1 2026 net income of $331.0 million, a significant turnaround, driven by collaboration revenue. The company also provided positive updates on its siRNA pipeline and regulatory submissions for existing therapies, while reaffirming its full-year guidance.
Key Events · Earnings and Guidance · SRPT
-
Significant GAAP Net Income Turnaround
Sarepta reported a GAAP net income of $331.0 million for Q1 2026, a substantial improvement from a net loss of $447.5 million in Q1 2025.
-
Q1 Revenue Details & ELEVIDYS Sales
Total revenues were $730.8 million, a slight decrease from $744.9 million in Q1 2025. This was primarily due to lower ELEVIDYS product sales ($102.0 million) following label updates, largely offset by $365.0 million in collaboration revenue related to a Roche option decline and a Japan milestone payment.
-
Positive Early siRNA Pipeline Data
The company shared encouraging early clinical results from Phase 1/2 studies of SRP-1001 (FSHD1) and SRP-1003 (DM1), demonstrating dose-dependent drug exposure, early biomarker effects, and favorable tolerability.
-
Regulatory Progress for PMO Therapies
Sarepta submitted sNDAs to the FDA seeking conversion of AMONDYS 45 and VYONDYS 53 from accelerated to traditional approvals, supported by confirmatory study data.
Analysis · SRPT · Life Sciences
Sarepta Therapeutics announced a significant financial turnaround in Q1 2026, reporting a GAAP net income of $331.0 million, a substantial improvement from a prior-year loss. This profitability was largely driven by collaboration revenue, which offset a slight decrease in total revenues primarily due to updated labeling for ELEVIDYS. The company also provided positive updates on its pipeline, including encouraging early clinical data for its siRNA programs targeting FSHD1 and DM1, and regulatory progress for its PMO therapies. The reiteration of full-year 2026 guidance signals stability in its outlook, despite the challenges with ELEVIDYS product sales. This filing provides comprehensive details to the Q1 results, which were also reported in a simultaneous 10-Q.
At the time of this filing, SRPT was trading at $21.95 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.4B. The 52-week trading range was $10.42 to $63.92. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.